Natalie McNamee

Natalie McNamee

Private Equity Investor chez
Tarnagulla Ventures Pty Ltd.
Consumer Services
Health Technology
Finance

Profil

Natalie has been a Director of Tarnagulla Ventures Pty Ltd since 2015.
She had led the investment diligence into most of the portfolio companies since then, including Lubris BioPharma, a company which has since successfully licensed their lead indication to Novartis.
Prior to returning to Australia, Natalie worked for Tocagen Inc, a gene therapy company, based in San Diego, in their business development team whilst finishing her Masters.
She then worked as a bioengineer at the then-newly formed Quanticel Pharmaceuticals, a cancer stem cell focused drug developer.
Quanticel was acquired by Celgene for $485M in 2015.
Natalie received her Masters in Bioengineering at UC San Diego and a dual Bachelor of Finance and Mechanical Engineering from Melbourne University.

Postes actifs de Natalie McNamee

SociétésPosteDébut
Private Equity Investor 01/01/2015

Anciens postes connus de Natalie McNamee

Formation de Natalie McNamee

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

1

Relations au 1er degré

4

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées4

Consumer Services

Consumer Services

Health Technology

Finance

  1. Bourse
  2. Insiders
  3. Natalie McNamee